<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Kare Mobile Incorporated

    Kare Mobile Incorporated

    Kare is the new mobile dental platform on the market for concierge style dental tr...

    Kare is the new mobile dental platform on the m...

    Amount Raised:    $17,742.00
    Fundraising Status:    EC
    Filing Type:    CF
    Bioanalytical Systems, Inc.

    Bioanalytical Systems, Inc.

    BASi provides drug discovery and development services and analytical instruments t...

    BASi provides drug discovery and development se...

    Filing Type:    PU
    Ocugen, Inc.

    Ocugen, Inc.

    Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...

    Ocugen is a clinical stage biopharmaceutical co...

    Filing Type:    PU
    IMAC Holdings, Inc.

    IMAC Holdings, Inc.

    IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...

    IMAC Holdings, Inc. owns or manages IMAC Regene...

    Filing Type:    PU
    Intellia Therapeutics, Inc.

    Intellia Therapeutics, Inc.

    Intellia Therapeutics is a leading genome editing company focused on developing cu...

    Intellia Therapeutics is a leading genome editi...

    Filing Type:    PU
    Celldex Therapeutics, Inc.

    Celldex Therapeutics, Inc.

    Celldex is developing targeted therapeutics to address devastating diseases for wh...

    Celldex is developing targeted therapeutics to ...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Sierra Oncology, Inc.

    Sierra Oncology, Inc.

    Sierra Oncology is a clinical stage drug development company advancing targeted th...

    Sierra Oncology is a clinical stage drug develo...

    Filing Type:    PU
    NantKwest, Inc.

    NantKwest, Inc.

    NantKwest is an innovative clinical-stage immunotherapy company focused on harness...

    NantKwest is an innovative clinical-stage immun...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.